Life Technologies to Help Identify up to 20,000 Human Remains Found in Libya’s Mass Graves

GLASGOW, Scotland, January 30, 2013 /PRNewswire/ –

Humanitarian project will set up infrastructure, provide expert training,

validate and process samples

Life Technologies [http://www.lifetechnologies.com/us/en/home.html ] Corporation
(NASDAQ: LIFE) today announced it will provide a complete laboratory solution to identify
an estimated 20,000 human remains found in various mass graves in Libya following the
uprising of 2011 and to address missing persons cases from the 42-year regime of Muammar
Gaddafi. This identification work is expected to take several years.

Life Technologies, a leader in forensic DNA technologies, will provide the
infrastructure, including the expertise, training, and the forensic instruments and
materials to validate the workflow and process DNA samples through its Dubai-based
distributor Integrated Gulf Biosystems (IGB) [http://www.igbiosystems.com/index.aspx ].

“It is our hope that many families will find the answers to what happened to their
loved ones,” said Peter Silvester, President, Life Technologies, Europe, Middle East &
Africa. “By providing the laboratory setup and forensic expertise we will help train
Libyan scientists in the very latest instruments, technology and protocols to enable them
in their work and help promote reconciliation in Libya.”

Life Technologies will create two separate DNA lines – one geared toward reference
samples and the second focusing on processing samples from human remains. Fifty-thousand
samples will be processed per year. Human remains samples will be processed using
PrepFiler(R) BTA
[https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=608882 ]
chemistry optimized to isolate DNA from bones and teeth in combination with AmpFlSTR(R)
NGM SElect(TM) PCR Amplification Kit
[https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=606840&tab=DetailInfo ]
and MiniFiler(TM) Kit,
[http://marketing.appliedbiosystems.com/mk/get/MINIFILER_LANDING ] designed for heavily
degraded samples. Reference samples will be processed using direct amplification
technology combining Copan NUCLEIC-CARD(TM)
[https://products.invitrogen.com/ivgn/product/4473974?ICID=search-product5 ] with NGM
SElect(TM) Express
[https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=608993 ]
.

The laboratory will utilise the latest generation of genetic analysers and ancillary
equipment and will be functionally validated under the quality assurance standards and
guidelines required by the ASCLAD-LAB, SWGDAM and ISO 17025. Some training of Libyan
scientists will take place in the United States under the direction and supervision of Dr.
Arthur Eisenberg
[https://profile.hsc.unt.edu/profilesystem/viewprofile.php?pid=10045070&onlyview=1 ], a
world renowned forensic scientist, leading up to the lab’s opening in Tripoli.

“The University of North Texas Health Science Center, [http://www.hsc.unt.edu ] with
its extensive experience in the identification of missing persons and human decedents, is
extremely pleased to partner with Life Technologies in the training of the Libyan forensic
scientists to help them complete their mission,” said Dr. Eisenberg, Director of the UNT
Center for Human Identification [http://www.hsc.unt.edu/departments/Forensics/Center for
Human Identification.cfm ].

The humanitarian project is funded in part by Repsol
[http://www.repsolenergy.com/index.html ], a Spanish-based oil company which donated to the
Libyan government through its foundation, $2.5 million in 2012 to help establish a
state-of-the-art laboratory to identify and generate profiles from human remains and
references from associated relatives of missing people.

AmpFlSTR(R) NGM SElect(TM) PCR Amplification Kit, Copan NUCLEIC-CARD(TM),
MiniFiler(TM) Kit and NGM SElect(TM) Express are for forensic and paternity use only.
PrepFiler(R) BTA is for research use only, not for use in diagnostic procedures.

Life Technologies Corporation
[http://www.lifetechnologies.com/us/en/home.html?cid=fl-home%3fCID=fl-home ] (NASDAQ: LIFE
[http://www.lifetechnologies.com/us/en/home.html?cid=fl-home%3fCID=fl-home ]) is a global
biotechnology company with customers in more than 160 countries using its innovative
solutions to solve some of today’s most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use solutions
spanning the biological spectrum, with more than 50,000 products for agricultural
biotechnology, translational research, molecular medicine and diagnostics, stem cell-based
therapies, forensics, food safety and animal health. Its systems, reagents and consumables
represent some of the most cited brands in scientific research including: Ion Torrent(TM),
Applied Biosystems(R), Invitrogen(TM), Gibco(R), Ambion(R), Molecular Probes(R) and
Novex(R). Life Technologies employs approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had
sales of $3.7 billion in 2011. Visit us at our website:

http://www.lifetechnologies.com.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results
that involve risks and uncertainties. Some of the information contained in this press
release, including, but not limited to, statements as to industry trends and Life
Technologies’ plans, objectives, expectations and strategy for its business, contains
forward-looking statements that are subject to risks and uncertainties that could cause
actual results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words “believe,” “plan,” “intend,”
“anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or
conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar
expressions, identify certain of these forward-looking statements. Important factors which
could cause actual results to differ materially from those in the forward-looking
statements are detailed in filings made by Life Technologies with the Securities and
Exchange Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.

SOURCE Life Technologies